AstraZeneca: Studies show antibody reduces COVID risk
November 18, 2021 at 04:22 AM EST
AstraZeneca PLC said Thursday Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.
